The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.
暂无分享,去创建一个
Mingyu Liang | Yi Fang | Yong Liu | Yong Liu | Mingyu Liang | A. Kriegel | Yi Fang | Xiaoqiang Ding | Xiaoqiang Ding | Alison J Kriegel | Alison J. Kriegel
[1] John Calvin Reed,et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.
[2] Akira Nakagawara,et al. p53: The Attractive Tumor Suppressor in the Cancer Research Field , 2010, Journal of biomedicine & biotechnology.
[3] V. Ambros,et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.
[4] Yong Liu,et al. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor β1: a novel role of miR-382 , 2010, Nucleic acids research.
[5] V. Nguyen. Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .
[6] R. Turner,et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma , 2011, Epigenetics.
[7] L. Wilhelmsen,et al. Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.
[8] E. Lütjen-Drecoll,et al. The effect of TGF-beta2 on elastin, type VI collagen, and components of the proteolytic degradation system in human optic nerve astrocytes. , 2008, Investigative ophthalmology & visual science.
[9] Wei Gu,et al. Modes of p53 Regulation , 2009, Cell.
[10] H. Soifer,et al. MicroRNAs in disease and potential therapeutic applications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] H. Jacob,et al. Dynamic convergence and divergence of renal genomic and biological pathways in protection from Dahl salt-sensitive hypertension. , 2010, Physiological genomics.
[12] S. Cohen,et al. microRNA functions. , 2007, Annual review of cell and developmental biology.
[13] S. Antonarakis,et al. Regulation of fibrinogen production by microRNAs. , 2010, Blood.
[14] Allen W. Cowley,et al. Renal Medullary MicroRNAs in Dahl Salt-Sensitive Rats: miR-29b Regulates Several Collagens and Related Genes , 2010, Hypertension.
[15] Xiongfei Xu,et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ , 2011, Nature Immunology.
[16] J P Rapp,et al. Dahl salt-susceptible and salt-resistant rats. A review. , 1982, Hypertension.
[17] R J Roman,et al. Genetically defined risk of salt sensitivity in an intercross of Brown Norway and Dahl S rats. , 2000, Physiological genomics.
[18] Arturo Sala,et al. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. , 2005, European journal of cancer.
[19] H. Haller,et al. MicroRNAs as mediators and therapeutic targets in chronic kidney disease , 2011, Nature Reviews Nephrology.
[20] T. Pabst,et al. The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML , 2010, British Journal of Cancer.
[21] Yong Zhao,et al. A developmental view of microRNA function. , 2007, Trends in biochemical sciences.
[22] Carlo M. Croce,et al. Biological Functions of miR-29b Contribute to Positive Regulation of Osteoblast Differentiation* , 2009, The Journal of Biological Chemistry.
[23] Mingyu Liang,et al. Molecular networks in Dahl salt-sensitive hypertension based on transcriptome analysis of a panel of consomic rats. , 2008, Physiological genomics.
[24] A. Cowley. The genetic dissection of essential hypertension , 2006, Nature Reviews Genetics.
[25] Paul D. P. Pharoah,et al. p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.
[26] Tint Lwin,et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. , 2010, Blood.
[27] R J Roman,et al. Brown Norway Chromosome 13 Confers Protection From High Salt to Consomic Dahl S Rat , 2001, Hypertension.
[28] Cheuk-Man Yu,et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. , 2011, Journal of the American Society of Nephrology : JASN.
[29] R. Watson,et al. Cell cycle regulation by the B-Myb transcription factor , 2003, Cellular and Molecular Life Sciences CMLS.
[30] Z. Jing,et al. A microRNA profile comparison between thoracic aortic dissection and normal thoracic aorta indicates the potential role of microRNAs in contributing to thoracic aortic dissection pathogenesis. , 2011, Journal of vascular surgery.
[31] Torsten Haferlach,et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.
[32] R. D'Agostino,et al. Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population , 2000, Circulation.
[33] H Tunstall-Pedoe,et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.
[34] J. Qian,et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. , 2011, American journal of respiratory cell and molecular biology.
[35] Oliver Distler,et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. , 2010, Arthritis and rheumatism.
[36] S. Silbiger,et al. Serum-stimulated α1 type IV collagen gene transcription is mediated by TGF-β and inhibited by estradiol. , 1998, American journal of physiology. Renal physiology.
[37] Tsung-Cheng Chang,et al. Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.
[38] G. Gronowicz,et al. miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop* , 2010, The Journal of Biological Chemistry.
[39] Thomas Manke,et al. MicroRNAs Differentially Expressed in Postnatal Aortic Development Downregulate Elastin via 3′ UTR and Coding-Sequence Binding Sites , 2011, PloS one.
[40] W. Meyer,et al. Comparison of aldosterone binding in aortic cells from Dahl salt-susceptible and salt-resistant rats. , 1985, Life sciences.
[41] Z. Galis,et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.
[42] C. Croce,et al. MicroRNA 29b functions in acute myeloid leukemia. , 2009, Blood.
[43] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[44] H. Lan,et al. Transforming growth factor-β and Smads. , 2011, Contributions to nephrology.
[45] Jinqiao Qian,et al. The role of microRNA in modulating myocardial ischemia-reperfusion injury. , 2011, Physiological genomics.
[46] K. Pandit,et al. MicroRNAs in idiopathic pulmonary fibrosis. , 2011, Translational research : the journal of laboratory and clinical medicine.
[47] D. Epstein,et al. Cross-talk between miR-29 and transforming growth factor-betas in trabecular meshwork cells. , 2011, Investigative ophthalmology & visual science.
[48] Jeffrey E. Thatcher,et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.
[49] Y. Pekarsky,et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression , 2010, Proceedings of the National Academy of Sciences.
[50] Brian S. Roberts,et al. The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[51] W. Filipowicz,et al. The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.
[52] P. Kantharidis,et al. TGF-β Regulates miR-206 and miR-29 to Control Myogenic Differentiation through Regulation of HDAC4 , 2011, The Journal of Biological Chemistry.
[53] S. Bronk,et al. Transcriptional suppression of mir‐29b‐1/mir‐29a promoter by c‐Myc, hedgehog, and NF‐kappaB , 2010, Journal of cellular biochemistry.
[54] S. Kumar,et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. , 1996, Journal of molecular and cellular cardiology.
[55] Jin-Wu Nam,et al. miR-29 miRNAs activate p53 by targeting p85α and CDC42 , 2009, Nature Structural &Molecular Biology.
[56] J. S. Janicki,et al. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. , 2001, American journal of physiology. Heart and circulatory physiology.
[57] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[58] Mingyu Liang,et al. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. , 2008, Genome research.
[59] Muller Fabbri,et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.
[60] Hong Xu,et al. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. , 2009, Cancer research.
[61] W. Border,et al. Transforming Growth Factor β in Tissue Fibrosis , 1994 .
[62] J. Long,et al. MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy* , 2011, The Journal of Biological Chemistry.
[63] E. Olson,et al. Pervasive roles of microRNAs in cardiovascular biology , 2011, Nature.
[64] E. Sontheimer,et al. Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.
[65] M. Oren,et al. p53: Guardian of ploidy , 2011, Molecular oncology.
[66] C M Croce,et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[67] Paul Ahlquist,et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins , 2008, Proceedings of the National Academy of Sciences.
[68] Zhaoyong Hu,et al. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. , 2010, Cardiovascular research.
[69] K. Bhatt,et al. microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. , 2011, American journal of physiology. Renal physiology.
[70] Y. Liu,et al. MicroRNA: a new frontier in kidney and blood pressure research. , 2009, American journal of physiology. Renal physiology.
[71] D. Ma,et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV‐related target genes for miR‐29 , 2011, The Journal of pathology.
[72] Hui Zhou,et al. High glucose down‐regulates miR‐29a to increase collagen IV production in HK‐2 cells , 2010, FEBS letters.
[73] K. Yoshizato,et al. Suppression of hepatic stellate cell activation by microRNA-29b. , 2011, Biochemical and biophysical research communications.
[74] Y. Pekarsky,et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. , 2006, Cancer research.
[75] K. Zatloukal,et al. miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis , 2009, EMBO reports.
[76] C. Morrison,et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.
[77] J. Hernandez,et al. Comments on nomenclature of TOM genes/proteins and characterization of psi4Tom20, a novel processed pseudogene of the human Tom20 gene. , 2000, Genomics.
[78] Mingyu Liang. MicroRNA: a new entrance to the broad paradigm of systems molecular medicine. , 2009, Physiological genomics.
[79] C. Coffill,et al. The role of mutant p53 in human cancer , 2011, The Journal of pathology.
[80] Shuang Huang,et al. Uracils at nucleotide position 9–11 are required for the rapid turnover of miR-29 family , 2011, Nucleic acids research.
[81] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[82] E. Olson,et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.
[83] Hui Zhou,et al. Deep Sequencing of Human Nuclear and Cytoplasmic Small RNAs Reveals an Unexpectedly Complex Subcellular Distribution of miRNAs and tRNA 3′ Trailers , 2010, PloS one.
[84] Huating Wang,et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. , 2008, Cancer cell.
[85] Jan A Staessen,et al. Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.
[86] M. Olivier,et al. Insights into Dahl salt-sensitive hypertension revealed by temporal patterns of renal medullary gene expression. , 2003, Physiological genomics.
[87] M. Irigoyen,et al. MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. , 2011, Physiological genomics.
[88] C. Prives,et al. Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.
[89] Mitsuo Kato,et al. MicroRNAs and their role in progressive kidney diseases. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[90] M. Vinciguerra,et al. MicroRNA-29 in Aortic Dilation: Implications for Aneurysm Formation , 2011, Circulation research.
[91] T. Luedde,et al. Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis , 2011, Hepatology.
[92] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[93] A. Folsom,et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.
[94] Kazufumi Suzuki,et al. Recent Advances in p53 Research and Cancer Treatment , 2011, Journal of biomedicine & biotechnology.
[95] J. Yun,et al. Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma , 2009, Hepatology.
[96] J. Laine,et al. The protooncogene TCL1 is an Akt kinase coactivator. , 2000, Molecular cell.
[97] Xiaopu Liu,et al. Transforming growth factor-beta1 up-regulation of human alpha(1)(I) collagen is mediated by Sp1 and Smad2 transacting factors. , 2009, DNA and cell biology.
[98] G. Gores,et al. mir-29 regulates Mcl-1 protein expression and apoptosis , 2007, Oncogene.
[99] C. Croce,et al. Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling Networks* , 2009, The Journal of Biological Chemistry.
[100] S. Gammeltoft,et al. Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes , 2011, British journal of pharmacology.
[101] Ana Kozomara,et al. miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..
[102] Y. Pekarsky,et al. Is miR-29 an oncogene or tumor suppressor in CLL? , 2010, Oncotarget.
[103] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[104] D. Bluemke,et al. Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). , 2010, American heart journal.
[105] E. Wentzel,et al. A Hexanucleotide Element Directs MicroRNA Nuclear Import , 2007, Science.
[106] J. Foster,et al. Activation of elastin transcription by transforming growth factor-beta in human lung fibroblasts. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[107] F. Spinale,et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.